RNA and nanocarriers: next generation drug and delivery platform take center stage

The unprecedented rapid deployment of mRNA vaccines against COVID-19 can be traced back to the early studies of RNA nanocarriers, including the study by Zimmermann et al. which showcased the effectiveness of RNA nanocarriers in vivo. This study, among others, ultimately resulted in Onpattro, the first FDA-approved RNA formulation.

Automated summary

The rapid deployment of mRNA vaccines against COVID-19 is possible due to early studies on RNA nanocarriers, specifically the study by Zimmermann et al. that demonstrated the efficacy of RNA nanocarriers in vivo. This study, along with others, eventually led to the development of Onpattro, the first FDA-approved RNA formulation.